Authors say findings do not support routine hormone use in the perimenopausal and postmenopausal periods
TUESDAY, May 6, 2025 (HealthDay News) — Hormone therapy use is linked to worse bladder health in postmenopausal women, according to a study published online April 29 in Menopause.
Camille P. Vaughan, M.D., from the Atlanta VA Geriatric Research Education and Clinical Center at Emory University, and colleagues evaluated associations between menopause status and hormone use with bladder health and lower urinary tract symptoms (LUTS). The analysis included 3,126 community-dwelling adult women.
The researchers found that across multiple bladder health scales and bladder function indices, perimenopause and postmenopause status were associated with worse scores versus premenopause status. Perimenopausal women were more likely to report urgency urinary incontinence (odds ratio, 2.27) and other LUTS versus premenopausal women. In postmenopausal women, hormone use was associated with worse bladder health.
“While it is not possible to determine the directionality of the association between hormone use and bladder health and LUTS, these results do not support routine recommendations for hormone use in the perimenopausal and postmenopausal periods,” the authors write. “Future research should continue to investigate the nuances of this relationship, enabling more effective prevention and management strategies for women with and without LUTS before and during menopause.”
Two authors disclosed ties to the medical technology industry.
Abstract/Full Text (subscription or payment may be required)
Estrogen Hormone Treatment May Be Beneficial for Brain Fog Symptoms in Menopausal Women
Menopausal Hormone Therapy Use Linked to Lower Risk for Alzheimer Disease
AMH Predicts Benefit of Chemo + Endocrine Therapy in Under 55s With Breast Cancer
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes
Add-On Tirzepatide May Reduce MACE Risk in People With T2D, ASCVD
Premature Menopause Linked to Increased Risk for Hypertension
Semaglutide Not Linked to Higher Neovascular Age-Related Macular Degeneration Risk